The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Oral administration with concomitant charcoal.
Oral administration without concomitant charcoal.
Clinical Reseach Services Turku (CRST)
Turku, Finland
The evaluation of primary pharmacokinetic variable AUCt
The evaluation of primary pharmacokinetic variable AUCt of this study will be based on statistical methods appropriate for crossover design.
Time frame: 4 weeks
Pharmacokinetic variables
Cmax
Time frame: 4 weeks
Pharmacokinetic variable
tmax
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.